Daniel H. Present

24.0k total citations · 9 hit papers
135 papers, 17.9k citations indexed

About

Daniel H. Present is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Daniel H. Present has authored 135 papers receiving a total of 17.9k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Genetics, 82 papers in Epidemiology and 48 papers in Surgery. Recurrent topics in Daniel H. Present's work include Inflammatory Bowel Disease (97 papers), Microscopic Colitis (64 papers) and Autoimmune and Inflammatory Disorders (24 papers). Daniel H. Present is often cited by papers focused on Inflammatory Bowel Disease (97 papers), Microscopic Colitis (64 papers) and Autoimmune and Inflammatory Disorders (24 papers). Daniel H. Present collaborates with scholars based in United States, Belgium and Canada. Daniel H. Present's co-authors include Stephen B. Hanauer, Paul Rutgeerts, Sander J. H. van Deventer, T Schaible, Kimberly L. DeWoody, Bruce E. Sands, Burton I. Korelitz, William J. Sandborn, Brian G. Feagan and Stephan R. Targan and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Daniel H. Present

131 papers receiving 17.2k citations

Hit Papers

Infliximab for Induction and Maintenanc... 1980 2026 1995 2010 2005 1997 1999 1999 1980 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
    2005 2.9k citations Paul Rutgeerts, William J. Sandborn et al. profile →
  2. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
    1997 2.5k citations Stephan R. Targan, Stephen B. Hanauer et al. profile →
  3. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
    1999 2.0k citations Daniel H. Present, Stephen B. Hanauer et al. profile →
  4. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
    1999 875 citations Paul Rutgeerts, Stephan R. Targan et al. Gastroenterology profile →
  5. Treatment of Crohn's Disease with 6-Mercaptopurine
    1980 766 citations Daniel H. Present, David B. Sachar et al. profile →
  6. Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
    2011 693 citations Jean‐Frédéric Colombel, Paul Rutgeerts et al. Gastroenterology profile →
  7. Anti–Interleukin-12 Antibody for Active Crohn's Disease
    2004 628 citations Lloyd Mayer, William J. Sandborn et al. profile →
  8. 6-Mercaptopurine in the Management of Inflammatory Bowel Disease: Short- and Long-Term Toxicity
    1989 571 citations Daniel H. Present et al. profile →
  9. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
    2002 515 citations William J. Sandborn, Brian G. Feagan et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel H. Present United States 48 13.5k 10.1k 5.4k 4.0k 2.0k 135 17.9k
William J. Tremaine United States 70 13.7k 1.0× 11.0k 1.1× 7.2k 1.3× 2.0k 0.5× 1.4k 0.7× 268 19.3k
Gary R. Lichtenstein United States 35 12.0k 0.9× 9.7k 1.0× 4.0k 0.7× 3.1k 0.8× 1.1k 0.6× 130 14.3k
Walter Reinisch Austria 57 14.1k 1.0× 11.0k 1.1× 5.3k 1.0× 4.0k 1.0× 1.0k 0.5× 340 19.9k
Douglas C. Wolf United States 35 10.8k 0.8× 8.4k 0.8× 3.6k 0.7× 3.6k 0.9× 1.3k 0.7× 114 13.3k
Jack Satsangi United Kingdom 58 9.4k 0.7× 6.3k 0.6× 4.0k 0.7× 3.1k 0.8× 968 0.5× 222 13.2k
Allan Olson United States 28 8.9k 0.7× 6.9k 0.7× 2.5k 0.5× 3.0k 0.8× 744 0.4× 74 11.0k
Filip Baert Belgium 42 8.6k 0.6× 6.6k 0.7× 3.1k 0.6× 2.8k 0.7× 655 0.3× 137 11.0k
Sandro Ardizzone Italy 50 6.9k 0.5× 5.2k 0.5× 3.6k 0.7× 1.5k 0.4× 1.1k 0.6× 236 10.7k
Jewel Johanns United States 32 8.6k 0.6× 6.5k 0.6× 2.3k 0.4× 3.4k 0.9× 750 0.4× 119 10.4k
Matthieu Allez France 55 6.2k 0.5× 5.0k 0.5× 3.2k 0.6× 3.3k 0.8× 638 0.3× 242 11.2k

Countries citing papers authored by Daniel H. Present

Since Specialization
Citations

This map shows the geographic impact of Daniel H. Present's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel H. Present with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel H. Present more than expected).

Fields of papers citing papers by Daniel H. Present

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel H. Present. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel H. Present. The network helps show where Daniel H. Present may publish in the future.

Co-authorship network of co-authors of Daniel H. Present

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel H. Present. A scholar is included among the top collaborators of Daniel H. Present based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel H. Present. Daniel H. Present is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sandborn, William J., Paul Rutgeerts, Brian G. Feagan, et al.. (2009). Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab. Gastroenterology. 137(4). 1250–1260. 356 indexed citations
2.
Katz, Jennifer, Elana Maser, Thomas Ullman, et al.. (2009). W1105 Cyclosporine and Infliximab As Delayed Salvage Therapy for Each Other in Patients with Steroid-Refractory Ulcerative Colitis. Gastroenterology. 136(5). A–655. 2 indexed citations
3.
Murphy, Seamus, et al.. (2009). Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45 years: a proposed method. Alimentary Pharmacology & Therapeutics. 30(10). 1078–1086. 5 indexed citations
4.
Murphy, Seamus, et al.. (2008). Adverse Events Associated With the Use of Cyclosporine in Patients With Inflammatory Bowel Disease. The American Journal of Gastroenterology. 103(4). 937–943. 76 indexed citations
5.
Marion, James F., Jerome D. Waye, Daniel H. Present, et al.. (2008). Chromoendoscopy-Targeted Biopsies Are Superior to Standard Colonoscopic Surveillance for Detecting Dysplasia in Inflammatory Bowel Disease Patients: A Prospective Endoscopic Trial. The American Journal of Gastroenterology. 103(9). 2342–2349. 215 indexed citations
6.
Sandborn, William J., P. Rutgeerts, Brian G. Feagan, et al.. (2007). Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Analysis from ACT 1 and ACT 2. The American Journal of Gastroenterology. 102. S479–S480. 2 indexed citations
7.
Targan, Stephan R., Brian G. Feagan, Richard N. Fedorak, et al.. (2007). Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial. Gastroenterology. 132(5). 1672–1683. 459 indexed citations
8.
Lévy, Roger, et al.. (2005). Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. Alimentary Pharmacology & Therapeutics. 21(3). 243–249. 29 indexed citations
9.
Sandborn, William J., Daniel H. Present, Kim L. Isaacs, et al.. (2003). Tacrolimus for the treatment of fistulas in patients with crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology. 125(2). 380–388. 227 indexed citations
10.
Hanauer, Stephen B. & Daniel H. Present. (2003). The state of the art in the management of inflammatory bowel disease.. PubMed. 3(2). 81–92. 131 indexed citations
11.
Present, Daniel H.. (2002). Serologic Tests Are Not Helpful in Managing Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 8(3). 227–229. 8 indexed citations
12.
Present, Daniel H.. (1998). Management of fistula disease. Inflammatory Bowel Diseases. 4(4). 302–307. 11 indexed citations
13.
Banks, Peter A. & Daniel H. Present. (1997). Is the Prolonged Use of Low-Dose Steroids Safe for Crohnʼs Disease?. Inflammatory Bowel Diseases. 3(2). 174–175. 2 indexed citations
14.
Present, Daniel H. & Simon Lichtiger. (1994). Efficacy of cyclosporine in treatment of fistula of crohn's disease. Digestive Diseases and Sciences. 39(2). 374–380. 190 indexed citations
15.
Present, Daniel H.. (1993). Toxic Megacolon. Medical Clinics of North America. 77(5). 1129–1148. 31 indexed citations
16.
Bennett, R. Avery, Peter Rubin, & Daniel H. Present. (1991). Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology. 100(6). 1638–1643. 108 indexed citations
17.
Present, Daniel H.. (1989). 6-Mercaptopurine and Other Immunosuppressive Agents in the Treatment of Crohn’s Disease and Ulcerative Colitis. Gastroenterology Clinics of North America. 18(1). 57–71. 52 indexed citations
18.
19.
Meyers, Samuel, David B. Sachar, Daniel H. Present, & Henry D. Janowitz. (1987). Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. Gastroenterology. 93(6). 1255–1262. 13 indexed citations
20.
Gelernt, Irwin M., Daniel H. Present, & H. D. Janowitz. (1972). Alterations in serum immunoglobulins after resection for ulcerative and granulomatous disease of the intestine. Gut. 13(1). 21–23. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William J. Tremaine Breakdown of academic impact, for papers by Gary R. Lichtenstein Breakdown of academic impact, for papers by Walter Reinisch Breakdown of academic impact, for papers by Douglas C. Wolf Breakdown of academic impact, for papers by Jack Satsangi Breakdown of academic impact, for papers by Allan Olson Breakdown of academic impact, for papers by Filip Baert Breakdown of academic impact, for papers by Sandro Ardizzone Breakdown of academic impact, for papers by Jewel Johanns Breakdown of academic impact, for papers by Matthieu Allez
Rankless by CCL
2026